The legal landscape for the pharmaceutical industry is also continuously changing. To successfully traverse that landscape requires strong intellectual property and a pathway through the regulatory terrain, challenges faced in the life of every new drug. Companies and universities now often combine efforts, resources, and roles to bring a drug to market. These relationships add yet another dimension to the legal landscape for pharmaceuticals. This conference will look across that landscape and give direction for charting a course. Focusing on current issues, industry experts will address what is happening today and look forward to what we can expect in the future

- MARKET RESULTS REVIEW 2008

Review of Russia and the CIS market results. Issues of import and export.
Government policy in the field of pharmaceuticals market regulation.
Past period results of the DLO (RF) (Additional Pharmacological Support) programme. Characteristics of the new operational scheme

-INVESTMENTS ATTRACTION

Key qualities that attract international investors. Prospects of pharmaceuticals sales growth. Improvement of conditions for producers’ development. Monitoring of compliance with international and national norms, optimization of supply chain, quality of the marketing

-SHARPENING COMPANIES’ COMPETITIVE EDGEEfficient management of pharmaceutical business on the international scale
Instruments of sharpening company’s competitive edge and enhancing efficiency; marketing approaches successfully developed and tested by the international practice. Key factors of 2008 that can change the characteristics of the world market

-FORECAST OF EMERGING MARKETS AND MECHANICS OF IMPROVING SALES ON THE EXISTING MARKETS

The needs of unstable markets and multifunctional areas. Choosing the most acceptable ways of improving operations

-QUESTIONS OF TAX RISKS AND OVERPAYMENTS

Profits tax. Justification of expenses. Unjustified tax benefit. The rule of “thin capitalisation”. Transfer pricing. Controlled foreign companies (expected changes in legislation, main priorities of the tax policy of the RF 2008-2010)

-M&A IN PHARMACEUTICAL INDUSTRY: THE RUSSIAN AND WORLD EXPERIENCE

Investment attractiveness of companies pre- and post-IPO. Company development strategy in the context of an emerging market. Questions of capital raising. Increased activity in the field of M&A

-GLOBAL DISTRIBUTION

Organisation of supply and distribution systems
General 2008 results of pharmaceutical market and its development forecasts for 2009-12
Characteristic features and leading companies, products, segments
Regional aspects of market development
Issues of capitalisation and characteristics of local pharmaceutical producers development
Distribution channels – pharmacies, distributors, pharmacy chains and globalisation features of this market segment

-INTELLECTUAL PROPERTY PROTECTION

The difference between the patents, trade marks and service marks. Useful models, industrial samples, patent disputes, enforcement of intellectual rights. Intellectual property evaluation. Licences, protection from unfair competition. Enforcement of industrial property rights. Naming the place of product origination. International experience of intellectual property protection mechanisms

-TRANSITION TO GMP

Transformation forecasts for the pharmaceutical industry in relation to its transition to the international quality standards

-ACCESS. INNOVATION.MOBILISATION. SECURITY

Creating conditions where pharmaceutical industry of Russia and the CIS could receive a more effective support and ensuring cooperation of this industry with parties interested in its results.
Access means a necessity to continue work aimed at speeding up of the new drugs registration process and resolving the issue of compensation of their value. Innovations are the efforts to create a single scientific base of the CIS pharmaceutical industry. Mobilisation means joining the forces of pharmaceutical industry and the main stakeholders. Security is connected to the necessity to improve the reliability and transparency of medicine supply channel. Development of a programme, which would put together government representatives, patients, scientific community and industry to resolve severe problems of pharmaceutical business in 2009

Download programme